Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
10.53
+0.01 (0.10%)
At close: Aug 5, 2026, 4:00 PM EDT
10.39
-0.14 (-1.33%)
After-hours: Aug 5, 2026, 7:50 PM EDT

Zevra Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
136.07106.4723.6127.4610.4628.65
Revenue Growth
119.40%350.92%-14.02%162.58%-63.50%115.61%
Gross Profit
132.9489.9916.225.2910.1226.59
Operating Income
86.52-62.94-87-49.6-42.517.73
Net Income
-0.5483.23-105.51-46.05-41.54-62.9
Earnings Per Share
0.921.35-2.28-1.30-0.78-2.11
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
221.57191.0169.567.7482.85112.35
Total Debt
1.563.2160.343.7714.121.59
Net Cash (Debt)
220.07127.819.223.9768.72110.76
Net Cash Growth
56.82%1289.18%-61.62%-65.12%-37.95%-
Net Cash Per Share
3.732.230.200.681.993.72

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
33.4-1.6-69.67-33.54-18.7210.44
Capital Expenditures
-0.78-0.84--0.3-0.09-0.1
Free Cash Flow
32.62-2.43-69.67-33.83-18.8110.34
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
97.70%84.52%68.59%92.09%96.72%92.81%
Operating Margin
63.59%-59.12%-368.47%-180.63%-406.44%26.98%
Pretax Margin
-0.72%81.41%-381.76%-167.69%-404.75%-29.74%
Profit Margin
-0.40%78.17%-446.85%-167.69%-397.24%-29.86%
FCF Margin
23.98%-2.29%-295.04%-123.20%-179.86%36.08%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
11.506.64----
Forward PE
18.5119.15102.50102.50102.5024.17
P/FCF Ratio
51.90----29.50
PS Ratio
4.574.7818.969.9115.1610.64